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Introductory Paragraph
Soft tissue sarcomas, which encompass approximately 10,700 diagnoses and 3800 deaths 
per year in the US1, exhibit remarkable histologic diversity, with more than 50 recognized 
subtypes2. However, knowledge of their genomic alterations is limited. We describe an 
integrative analysis of DNA sequence, copy number, and mRNA expression in 207 samples 
encompassing seven major subtypes. Frequently mutated genes included TP53 (17% of 
pleomorphic liposarcomas), NF1 (10.5% of myxofibrosarcomas and 8% of pleomorphic 
liposarcomas), and PIK3CA (18% of myxoid/round-cell liposarcomas). PIK3CA mutations 
in myxoid/round-cell liposarcomas were associated with AKT activation and poor clinical 
outcomes. In myxofibrosarcomas and pleomorphic liposarcomas, we found both point 
mutations and genomic deletions affecting the tumor suppressor NF1. Finally, we found that 
shRNA-based knockdown of several genes amplified in dedifferentiated liposarcoma, 
including CDK4 and YEATS4, decreased cell proliferation. Our study yields a detailed map 
of molecular alterations across diverse sarcoma subtypes and provides potential subtype-
specific targets for therapy.
Current knowledge of the key genomic aberrations in soft tissue sarcoma is limited to the 
most recurrent alterations or translocations. Subtypes with simple, near-diploid karyotypes 
bear few chromosomal rearrangements but have pathognomonic alterations: translocations 
in myxoid/round-cell liposarcoma (MRC) [t(12;16)(q13;p11), t(12;22)(q13;q12)] and 
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synovial sarcomas (SS) [t(X;18)(p11;q11)]; activating mutations in KIT or PDGFRA in 
gastrointestinal stromal tumors (GIST)3,4. The discovery of the latter mutations led to the 
clinical deployment of imatinib for the treatment of GIST5, providing a model for genotype-
directed therapies in molecularly defined sarcoma subtypes. Conversely, sarcomas with 
complex karyotypes, including dedifferentiated and pleomorphic liposarcoma, 
leiomyosarcoma, and myxofibrosarcoma, have no known characteristic mutations or fusion 
genes, although abnormalities are frequently observed in the Rb, p53, and specific growth-
factor signaling pathways6.
Recent large-scale analyses7–10 have established a standard for cancer genome studies, but 
soft tissue sarcomas have not yet been a focus of this type of effort. Given the urgent need 
for new treatments for the ~4000 patients who die each year in the US of soft tissue 
sarcoma1, we sought to identify novel genomic alterations that could serve as therapeutic 
targets. Here, we describe complementary genome and functional genetic analyses of seven 
subtypes of high-grade soft tissue sarcoma (Table 1 and Supplementary Table 1) to discover 
subtype-specific events. Several of our findings, detailed below, could have nearly 
immediate therapeutic implications.
To study the genomic alterations in sarcomas, we initially analyzed 47 tumor/normal DNA 
pairs encompassing six soft tissue sarcoma subtypes by sequencing 722 protein-coding and 
microRNA genes, followed by verifying discovered mutations with mass spectrometry-
based genotyping (see Methods, Supplementary Figure 1A, and Supplementary Table 2). 
The results revealed 28 somatic non-synonymous coding point mutations and 9 somatic 
insertions/deletions (indels) involving 21 genes in total (Table 2 and Supplementary Figure 
1B). No mutations were detected in microRNAs genes. We extended the analysis to an 
additional 160 tumors, where we genotyped each of the mutations found above and re-
sequenced exons of NF1 and ERBB4 in pleomorphic liposarcoma and myxofibrosarcoma, 
PIK3CA and KIT in myxoid/round cell liposarcoma, and CDH1 in dedifferentiated 
liposarcoma; this revealed nine additional mutations (Table 2 and Supplementary Table 3).
KIT was frequently mutated in GISTs and unexpectedly, in one myxoid/round cell 
liposarcoma sample (Supplementary Note). The next most frequently mutated genes 
observed within specific sarcoma subtypes were PIK3CA, in 18% of myxoid/round cell 
liposarcomas, TP53 in 17% of pleomorphic liposarcomas (interestingly, the only subtype in 
which mutations of this gene were found), and NF1 in 10.5% of myxofibrosarcomas and 8% 
of pleomorphic liposarcomas (Table 2 and Figure 1). Additional genes, including protein 
and lipid kinases, as well as known or candidate tumor suppressor genes, were found 
mutated in just one sample for each sarcoma subtype (Table 2, Figure 1, and Supplementary 
Note). Further studies will be needed to establish the functional impact of these mutations in 
sarcoma.
Below, we focus on three major specific genomic findings with therapeutic implications: 
point mutation and deletion of NF1 in a subset of soft tissue sarcomas, point mutation of 
PIK3CA in myxoid/round cell liposarcoma, and the complex pattern of amplification of 
chromosome 12q in dedifferentiated liposarcoma.
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Integrated analysis of DNA copy number, expression, and mutation data uncovered diverse 
alterations of the Neurofibromatosis type 1 gene (NF1) in several sarcoma subtypes. While 
germline and somatic inactivation of NF1 is associated with malignant peripheral nerve 
sheath tumors11 and GISTs in Neurofibromatosis type 1 patients12, no somatic NF1 
alterations have been reported in other sarcomas. We detected six point mutations and 
twelve genomic deletions encompassing the NF1 locus, occurring in both myxofibrosarcoma 
and pleomorphic liposarcoma (Table 2 and Figure 1, 2A–B; copy number analysis discussed 
further below). Two of the mutations, R304* and Q369*, were previously reported as 
germline mutations in patients with Neurofibromatosis type 113,14, while the other four 
mutations (three missense and one nonsense) have not been previously reported. In some 
tumors, biallelic inactivation was evident, with heterozygous point mutations accompanied 
by deletion of the wild-type allele and correspondingly reduced gene expression compared 
to normal adipose tissue15 in most cases (Figure 2B). Together, these data indicate a diverse 
pattern of NF1 aberrations in myxofibrosarcomas and pleomorphic liposarcomas. These 
results complement recent reports of NF1 alterations in lung cancers and glioblastomas7,8.
PIK3CA, encoding the catalytic subunit of phosphatidylinositol 3-kinase (PI3K), had one of 
the highest somatic mutation frequencies among the genes in this analysis (Table 2). 
Nucleotide substitutions in PIK3CA were initially detected in 4 of 21 myxoid/round-cell 
liposarcomas (MRCs). We measured the frequency of point mutations in PIK3CA in this 
subtype by genotyping an independent cohort of 50 MRCs16 for 13 common sites of 
PIK3CA mutation, including those discovered in our initial sequencing; mutations were 
detected in 9 additional patients (in total, 13 of 71). The mutations were clustered in two 
domains, the helical domain (E542K and E545K) and the kinase domain (H1047L and 
H1047R) (Table 2); both these domains are also mutated in epithelial tumors17.
MRC patients whose tumors harbored mutations in PIK3CA had a shorter duration of 
disease–specific survival than did those with wildtype PIK3CA (p=0.036, log-rank test). 
Similar to observations in breast cancers18, patients with helical-domain PIK3CA mutations 
had worse outcomes than those with kinase-domain mutations (Figure 3A). However, this 
difference was not statistically significant given the small number of cases in our study.
As both helical- and kinase-domain PIK3CA mutants are believed to activate Akt, although 
through different mechanisms19–21, we assessed Akt activation in MRC tumors harboring 
wildtype and mutated PIK3CA. Of note, only E545K helical-domain mutations were 
associated with increased Akt phosphorylation relative to wildtype, both at serine-473 and 
threonine-308 (TORC2 and PDK1 phosphorylation sites, respectively), and with increased 
phosphorylation of Akt substrates PRAS40 and S6 kinase (Figure 3B). Surprisingly, tumors 
with H1047R kinase-domain mutations did not have similar increases in Akt 
phosphorylation or activation (Figure 3B). However, H1047R-mutant tumors exhibited 
variably higher levels of PTEN, a negative regulator of PI3K activity, which may partly 
explain lower Akt activity. In addition, we detected a single MRC tumor with homozygous 
PTEN deletion and high Akt phosphorylation levels (data not shown). Further studies are 
needed to determine the relationship between activated PI3K signaling (resulting from 
PIK3CA mutations) and the pathognomonic t(12;16)(q13;p11) translocation in this subtype.
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In addition to sequencing, we characterized the spectrum of genomic aberrations in soft 
tissue sarcoma with 250K single nucleotide polymorphism (SNP) arrays for somatic copy 
number alterations (SCNAs: n=207; Figure 1 and Supplementary Figure 2A) and loss-of-
heterozygosity (LOH) (n=200; Supplementary Figure 2B) and with oligonucleotide gene 
expression arrays (n=149) (see Methods). The patterns of statistically significant 
SCNAs22,23 (Figure 1) revealed substantial differences between subtypes with simple and 
complex karyotypes (Figure 1). Myxoid/round-cell liposarcoma, synovial sarcoma, and 
GIST had relatively normal karyotypes compared to dedifferentiated and pleomorphic 
liposarcoma, leiomyosarcoma, and myxofibrosarcoma. In addition, only the four complex 
subtypes harbored significant copy-neutral LOH (Supplementary Figure 2B and 
Supplementary Table 4). These types exhibit varied levels of complexity: both 
dedifferentiated liposarcoma and leiomyosarcoma are less complex than pleomorphic 
liposarcoma and myxofibrosarcoma (Figure 1). The latter two subtypes were strikingly 
similar (Figure 1 and Supplementary Figure 2A), indicating they might appropriately be 
considered a single entity in a molecular classification, as previously suggested24.
Our copy number profiling revealed both focal and broad regions of recurrent amplification 
(Supplementary Table 5). The alteration with the highest prevalence in any subtype was 
chromosome 12q amplification in dedifferentiated liposarcoma (~90%; Figure 1 and Figure 
4A). As amplification is a common mechanism of oncogenic activation, we designed an 
RNA interference (RNAi) screen to help identify genes in amplified regions that are 
necessary for cancer cell proliferation in this subtype. We performed knockdown with short 
hairpin RNAs (shRNA) on 385 genes (Supplementary Table 2) in three dedifferentiated 
liposarcoma cell lines (LPS141, DDLS8817, and FU-DDLS-1) with copy number profiles 
similar to those observed in primary tumors of this subtype. A total of 2,007 shRNA 
lentiviruses, a median of five per gene, were tested for their effects on cell proliferation after 
5 days (see Methods).
Using a statistical method, RSA (see Methods, Supplementary Note, and ref. 25), we 
identified 99 genes whose knockdown significantly decreased cell growth in at least one cell 
line (nominal p<0.05; Supplementary Table 6). For 91 of the 99 genes, two or more 
independent shRNAs had anti-proliferative activity, reducing the likelihood that our results 
are due to off-target effects. To determine whether the effect of gene knockdown on cell 
proliferation was specific for dedifferentiated liposarcoma, we compared our results to a 
pooled shRNA screen of ~9500 genes in 12 cancer cell lines of different types26 which 
included 58 of the 99 genes whose knock-down reduced proliferation. Only one of the 58 
genes, PSMB4, was identified as a common essential gene, for which depletion reduced cell 
proliferation in ≥8 of 12 cancer cell lines in the prior study26.
27 of the 99 genes whose knockdown reduced proliferation were amplified in at least one of 
the three dedifferentiated liposarcoma cell lines used in our study (Supplementary Figure 3). 
Among these 27 genes, the most strongly overexpressed in dedifferentiated liposarcoma 
compared to normal fat15 was CDK4, a cell-cycle regulator and a known oncogene27. We 
confirmed that sustained knockdown of CDK4 (>10 days) inhibited proliferation when we 
assayed two of the three cell lines we screened (see Methods, Figure 4B). Furthermore, 
pharmacological inhibition of CDK4 in dedifferentiated liposarcoma cells with PD0332991, 
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a selective CDK4/CDK6 inhibitor currently in clinical trials28, induced G1 arrest in the 
same two cell lines (Figure 4C).
For MDM2, another oncogene found in focal 12q amplifications, knockdown did not 
significantly impair proliferation in our arrayed screen in any of the three cell lines tested. 
Nevertheless, proliferation was impaired by subsequent knockdown lasting more than a 
week when we assayed two of those three cell lines (Figure 4D). Interestingly, another gene 
whose knockdown reduced proliferation of cells in which it was amplified was YEATS4 
(GAS41), encoding a putative transcription factor that represses the p53 tumor suppressor 
network during normal cell proliferation29. YEATS4, frequently co-amplified with MDM2 
(Figure 4A), was transcriptionally upregulated both in tumors relative to normal adipose 
tissue and in tumors with amplification compared to those copy-neutral for the locus 
(Supplementary Figure 3). Repeat shRNA experiments confirmed the effect of YEATS4 
knockdown seen in the arrayed screen (Figure 4E), consistent with the hypothesis that 
YEATS4 and MDM2 amplification may cooperatively repress the p53 network in 
dedifferentiated liposarcoma, as recently suggested30. This finding may have consequences 
for Nutlin-based antagonism of the p53-MDM2 interaction15,31 in dedifferentiated 
liposarcomas. Our findings lend additional support for YEATS4 serving as a likely key 
amplified gene in cancer, as recently suggested through a weight-of-evidence classification 
scheme proposed for identifying such amplified cancer genes32.
This dataset provides the most comprehensive database of sarcoma genome alterations to 
date, revealing genes and signaling pathways not previously associated with this group of 
diseases. The study results are available as a community resource that might further the 
biological understanding of sarcomas and, eventually, shed light on additional strategies to 
improve patient care. Some of our findings already have potential therapeutic implications. 
For instance, the PIK3CA mutations found in MRC constitute the first report of such 
mutations in a mesenchymal cancer. These mutations identify a subset of tumors that might 
respond to treatment with PI3K inhibitors currently in clinical trials33. Our results also 
provide further rationale for use of CDK4 inhibitors in dedifferentiated liposarcoma and 
suggest the use of mTOR inhibitors in NF1-deficient sarcomas, since loss of NF1 function 
appears to cause mTOR pathway activation34. Finally, these data lend support for the 
clinical evaluation of agents targeting the p53/MDM2 interaction in dedifferentiated 
liposarcoma.
This work argues for the therapeutic importance of genomic alterations in sarcoma and 
encourages us to pursue next-generation sequencing strategies that will continue to define 
the landscape of genomic aberrations in these deadly diseases.
Methods
Methods and any associated references are available in the online version of the paper at 
http://www.nature.com/naturegenetics/.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Nucleotide and copy number alterations in soft-tissue sarcoma subtypes
The statistical significance of genomic aberrations for each subtype is shown. RAE q-values 
[left axis; for visualization, q-values ≤ 0.05 are considered significant, corresponding false 
discovery rate (FDR) ≤ 5%] and scores (right axis) for gains and amplifications (red) and 
losses and deletions (blue) are plotted across the genome (chromosomes indicated at 
bottom). Genes harboring somatic nucleotide alterations in this study are indicated in each 
subtype in which they were discovered (Table 2).
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Figure 2. NF1 alterations in karyotypically complex sarcomas
A. Somatic mutations in the NF1 protein in myxofibrosarcoma and pleomorphic 
liposarcoma (black triangles) and the position of the RasGAP and Cral domains (dark and 
light green respectively) are juxtaposed to known mutations in malignant peripheral nerve 
sheath tumors (MPNSTs; open triangles). B. Transcript expression according to copy 
number and sequence status in myxofibrosarcoma and pleomorphic liposarcoma compared 
to normal adipose tissue samples (black/red and green respectively, log2 expression from 
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Affymetrix array profiling data; p-value=1.94×10−5, ANOVA; mutated tumors are 
indicated). One of the two R304* mutant tumors lacked expression data.
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Figure 3. Different effect of helical and kinase domain PIK3CA mutations on PI3K pathway 
activation and survival in myxoid/round-cell liposarcoma
A. Survival for patients with tumors that harbor helical-domain mutations (red) versus 
kinase-domain mutations (grey), and wildtype PIK3CA (blue). The analysis includes the 65 
patients for whom outcome information was available. Patients with mutations in either the 
helical or the kinase domain had a shorter disease–specific survival compared to those with 
wildtype PIK3CA (p-value = 0.0363, log-rank test). The difference in disease-specific 
survival between patients with helical-domain mutant tumors and those with wildtype 
PIK3CA tumors was significant (p-value=0.013, log-rank test). B. Western blots of myxoid/
round-cell liposarcoma tumor lysates comparing the phosphorylation levels of Akt, 
PRAS40, and S6 kinase, as well as their protein levels, in patients with wild-type PIK3CA or 
with mutations in PIK3CA helical or kinase domains.
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Figure 4. Genes whose knockdown is anti-proliferative in dedifferentiated liposarcoma and the 
consequences of CDK4, MDM2 and YEATS4 knockdown in dedifferentiated liposarcoma
(A) Integrated profile of statistically significant genomic gains/amplifications as assessed by 
both RAE and GISTIC (combined as described in Methods; FDR, false-discovery rate) is 
followed by a heatmap of copy number segmentation on 12q13.2-q32.1 in 50 patient 
samples of dedifferentiated liposarcomas (red is amplification, blue is deletion, each row 
indicates one tumor sample). Below is the position of genes from our screen encoded by this 
region of 12q whose knockdown is anti-proliferative in dedifferentiated liposarcoma. Bold 
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gene symbols indicate those whose amplification produced over-expression of its transcript 
or those over-expressed in tumor relative to normal adipose tissue. Genes in green are 
highlighted in panels B–C and E. Alternative genomic regions encoding genes not on 12q 
whose knockdown is anti-proliferative are also included. (B) Effect of three validated 
shRNAs targeting CDK4 on the proliferation of two cell lines, LPS141 and DDLS8817, at 
various time points (x-axis) with negative controls (pLKO empty vector and GFP473). 
Below are western blots showing the effect of shRNAs on levels of CDK4 protein (as 
indicated). (C) G1 arrest induced in LPS141 and DDLS8817 cell lines by treatment with the 
CDK4/CDK6 inhibitor PD0332991. MDA-MB-435 (Rb-positive) and H2009 (Rb-negative) 
were included as sensitive and insensitive controls. Error bars are s.d. of replicate 
measurements. (D–E) As in panel (B), effect on proliferation of three shRNAs targeting 
MDM2 (panel D) and YEATS4 (panel E) (negative controls: pLKO empty vector and 
scrambled shRNA) where each targeting shRNA resulted in reduced protein levels (at 
bottom). Error bars are propagated error from the ratio of mean and s.d. of measurements/
replicates to time 0.
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Table 1
Summary of clinical and pathologic information for 207 soft-tissue sarcoma patients
Characteristic Value
No. of patients 207
Age [mean±SD (range)] 56±16 (7–84)
Gender (%) †
  Female 102 (50.2)
  Male 101 (49.8)
Tumor size §
  0–5 cm 35 (17.4)
  5–10 cm 65 (32.3)
  10–15 cm 43 (21.4)
  >15 cm 58 (28.9)
Primary site (%) †
  Retro-intrabdominal 60 (29.6)
  Visceral
    Gastrointestinal 23 (11.3)
    Genitourinary 4 (2)
    Gynecological 1 (0.5)
  Thoracic 12 (5.9)
  Extremity 93 (45.8)
  Trunk 8 (3.9)
  Head and Neck 2 (1)
Stage at time of sample procurment ‡
  Primary 139 (68.8)
  Local recurrence 29 (14.4)
  Distant recurrence 34 (16.8)
Histology
  Dedifferentiated liposarcoma 50 (24.2)
  Myxoid/round cell liposarcoma 21 (10.1)
  Pleomorphic liposarcoma 24 (11.6)
  Leiomyosarcoma 27 (13)
  Gastrointestinal stromal tumor
    Epithelioid 4 (1.9)
    Spindle 11 (5.3)
    Mixed or unspecified 7 (3.4)
  Myxofibrosarcoma
    Myxofibrosarcoma 35 (16.9)
    Pleomorphic MFH 3 (1.5)
  Synovial sarcoma ‖
    Monophasic 19 (9.2)
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Characteristic Value
    Biphasic 4 (1.9)
Median follow-up (months) 35.65
Time to distant recurrence (months) 15.7
Co-morbidities 57 (27.5)
‖One synovial sarcoma not specified
Data available for §201, †203, and ‡202 patients respectively
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